Clinical Trials Logo

Clinical Trial Summary

Phase 2, randomized study to assess topically administered eyedrops of INV-102 compared to vehicle during 1-week dosing in participants with Acute Infectious Keratoconjunctivitis (AIK). Participants will return for a follow up visit 1 week after end of treatment.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05636228
Study type Interventional
Source Invirsa, Inc.
Contact Invirsa Call Center
Phone +1 614-334-1765
Email info@invirsa.com
Status Recruiting
Phase Phase 2
Start date June 9, 2023
Completion date June 2024